H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study

Juan Alfonso Soler, Mercé Güell, Meritxell Bricullé, Antoni Gavarró, Imma Roig, Jordi Sanchez, Javier P. Gisbert, Pilar García, Albert Villoria, Xavier Calvet

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological alteration that carries a 1% risk per year of malignant evolution. The origin of this disturbance remains unknown. Previous reports have suggested that a subgroup of patients presenting MGUS might cure after Helicobacter pylori eradication. This study evaluates the effect of H. pylori eradication in a cohort of 30 patients with MGUS. A 7-day clarithromycin-based triple treatment was prescribed to patients with MGUS infected with H. pylori. Quantification of the monoclonal component was performed at inclusion and at least 12 months after treatment. The monoclonal component persisted unchanged in all patients who cured the H. pylori infection. © Springer-Verlag 2009.
Original languageEnglish
Pages (from-to)769-773
JournalAnnals of Hematology
Volume88
DOIs
Publication statusPublished - 23 Jan 2009

Keywords

  • Eradication therapy
  • Helicobacter pylori
  • Monoclonal gammopathy of unknown significance

Fingerprint Dive into the research topics of 'H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study'. Together they form a unique fingerprint.

Cite this